Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2-Reference-Cited by-同舟云学术

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

Published:2016-11-30 Issue:367 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Arenas-Ramirez Natalia¹,Zou Chao²,Popp Simone²,Zingg Daniel³,Brannetti Barbara²,Wirth Emmanuelle²,Calzascia Thomas²,Kovarik Jiri²,Sommer Lukas³,Zenke Gerhard²,Woytschak Janine¹,Regnier Catherine H.²,Katopodis Andreas²,Boyman Onur¹

Affiliation:

1. Department of Immunology, University Hospital Zurich, University of Zurich, CH-8091 Zurich, Switzerland.

2. Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.

3. Stem Cell Biology, Institute of Anatomy, University of Zurich, CH-8057 Zurich, Switzerland.

Abstract

An antibody to human IL-2 phenocopies CD25 and improves IL-2–based cancer immunotherapy.

Funder

Swiss National Science Foundation

Swiss Cancer League

Hochspezialisierte Medizin Schwerpunkt Immunologie

Helmut Horten Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference35 articles.

1. Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity

2. The role of interleukin-2 during homeostasis and activation of the immune system

3. Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

4. Interleukin-2: Biology, Design and Application

5. The IL-2/IL-2 receptor system: A current overview

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-2 immunotherapy rescues irradiation-induced T cell exhaustionin vivo;2024-01-31

2. Engineering Anticytokine Antibodies for Immune Modulation;The Journal of Immunology;2024-01-15

3. NK cells as powerful therapeutic tool in cancer immunotherapy;Cellular Oncology;2024-01-03

4. Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma;European Journal of Pharmacology;2024-01

5. The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024;International Archives of Allergy and Immunology;2023-12-12